GlassScriptPhysician profile
Nabil Altememi
NPI 1699096529
$2,135.97
in general payments reported to CMS, 2019-2025
13 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.23 · 2020: $160 · 2021: $104 · 2022: $1,084 · 2023: $221 · 2024: $79.93 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $691.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,158.85 | 2022-2023 | Inspire |
| Abbvie INC. | $313.19 | 2021-2025 | Ubrelvy |
| Jazz Pharmaceuticals INC. | $145.92 | 2020-2024 | |
| Argenx US, INC. | $122.03 | 2025 | Vyvgart |
| Philips North America LLC | $96.23 | 2019 | |
| Axsome Therapeutics, INC. | $92.53 | 2025 | Symbravo, Sunosi |
| Eisai INC. | $43.57 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $39.72 | 2025 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $39.38 | 2021 | |
| Pfizer INC. | $26.81 | 2025 | |
| Allergan, INC. | $23.73 | 2020 | |
| Abbott Laboratories | $19.28 | 2021 | |
| Csl Behring | $14.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Altememi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.